Evolving BioAssay Ontology (BAO): modularization, integration and applications

被引:48
作者
Abeyruwan, Saminda [1 ]
Vempati, Uma D. [2 ]
Kuecuek-McGinty, Hande [1 ]
Visser, Ubbo [1 ]
Koleti, Amar [2 ]
Mir, Ahsan [2 ]
Sakurai, Kunie [3 ]
Chung, Caty [2 ]
Bittker, Joshua A. [5 ]
Clemons, Paul A. [5 ]
Brudz, Steve [5 ]
Siripala, Anosha [6 ]
Morales, Arturo J. [6 ]
Romacker, Martin [6 ]
Twomey, David [6 ]
Bureeva, Svetlana [7 ]
Lemmon, Vance [2 ,3 ]
Schuerer, Stephan C. [2 ,4 ]
机构
[1] Univ Miami, Dept Comp Sci, Coral Gables, FL 33146 USA
[2] Univ Miami, Ctr Computat Sci, Coral Gables, FL 33146 USA
[3] Miami Project Cure Paralysis, Miami, FL 33136 USA
[4] Univ Miami, Sch Med, Dept Mol & Cellular Pharmacol, Miami, FL 33136 USA
[5] 7 Cambridge Ctr, Cambridge, MA 02142 USA
[6] Novartis Inst BioMed Res, Cambridge, MA 02139 USA
[7] Thomson Reuters, Carlsbad, CA 92008 USA
来源
JOURNAL OF BIOMEDICAL SEMANTICS | 2014年 / 5卷
基金
美国国家卫生研究院;
关键词
Resource Description Framework; Description Logic; Measure Group; Luciferase Reporter Gene Assay; Basic Formal Ontology;
D O I
10.1186/2041-1480-5-S1-S5
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
The lack of established standards to describe and annotate biological assays and screening outcomes in the domain of drug and chemical probe discovery is a severe limitation to utilize public and proprietary drug screening data to their maximum potential. We have created the BioAssay Ontology (BAO) project (http://bioassayontology.org) to develop common reference metadata terms and definitions required for describing relevant information of low- and high-throughput drug and probe screening assays and results. The main objectives of BAO are to enable effective integration, aggregation, retrieval, and analyses of drug screening data. Since we first released BAO on the BioPortal in 2010 we have considerably expanded and enhanced BAO and we have applied the ontology in several internal and external collaborative projects, for example the BioAssay Research Database (BARD). We describe the evolution of BAO with a design that enables modeling complex assays including profile and panel assays such as those in the Library of Integrated Network-based Cellular Signatures (LINCS). One of the critical questions in evolving BAO is the following: how can we provide a way to efficiently reuse and share among various research projects specific parts of our ontologies without violating the integrity of the ontology and without creating redundancies. This paper provides a comprehensive answer to this question with a description of a methodology for ontology modularization using a layered architecture. Our modularization approach defines several distinct BAO components and separates internal from external modules and domain-level from structural components. This approach facilitates the generation/extraction of derived ontologies (or perspectives) that can suit particular use cases or software applications. We describe the evolution of BAO related to its formal structures, engineering approaches, and content to enable modeling of complex assays and integration with other ontologies and datasets.
引用
收藏
页数:22
相关论文
共 27 条
  • [1] [Anonymous], P 5 INT WORKSH OWL E
  • [2] [Anonymous], 2010, J BIOMED SEMAN S, DOI DOI 10.1186/2041-1480-1-S1-S7
  • [3] NIH Molecular Libraries Initiative
    Austin, CP
    Brady, LS
    Insel, TR
    Collins, FS
    [J]. SCIENCE, 2004, 306 (5699) : 1138 - 1139
  • [4] Scientific competency questions as the basis for semantically enriched open pharmacological space development
    Azzaoui, Kamal
    Jacoby, Edgar
    Senger, Stefan
    Cuadrado Rodriguez, Emiliano
    Loza, Mabel
    Zdrazil, Barbara
    Pinto, Marta
    Williams, Antony J.
    de la Torre, Victor
    Mestres, Jordi
    Pastor, Manuel
    Taboureau, Olivier
    Rarey, Matthias
    Chichester, Christine
    Pettifer, Steve
    Blomberg, Niklas
    Harland, Lee
    Williams-Jones, Bryn
    Ecker, Gerhard F.
    [J]. DRUG DISCOVERY TODAY, 2013, 18 (17-18) : 843 - 852
  • [5] Baader F., 2010, DESCRIPTION LOGIC HD, V2nd
  • [6] Bento AP, 2013, NUCLEIC ACIDS RES AD, P1, DOI DOI 10.1093/NAR/GKT1031
  • [7] Callahan A, 2013, J BIOMEDICAL SEMA S1, V4, P1
  • [8] Ceusters Werner, 2006, AMIA Annu Symp Proc, P121
  • [9] Realism for scientific ontologies
    Dumontier, Michel
    Hoehndorf, Robert
    [J]. FORMAL ONTOLOGY IN INFORMATION SYSTEMS (FOIS 2010), 2010, 209 : 387 - 399
  • [10] ChEMBL: a large-scale bioactivity database for drug discovery
    Gaulton, Anna
    Bellis, Louisa J.
    Bento, A. Patricia
    Chambers, Jon
    Davies, Mark
    Hersey, Anne
    Light, Yvonne
    McGlinchey, Shaun
    Michalovich, David
    Al-Lazikani, Bissan
    Overington, John P.
    [J]. NUCLEIC ACIDS RESEARCH, 2012, 40 (D1) : D1100 - D1107